Johnson & Johnson Q3 2026 Earnings: Innovative Medicine Offsets MedTech Shortfall as Guidance Rises

Johnson & Johnson reported third-quarter sales of $25.4B, up 5.9% reported and 6.0% operationally, led by 7.9% operational growth in Innovative Medicine. GAAP EPS fell to $0.09 from $2.12 a year earlier, reflecting a proposed talc litigation resolution and expenses tied to recent business-development transactions, while adjusted EPS declined 7.5% to $2.59.

The quarter was operationally solid but financially mixed. Innovative Medicine continued to offset major patent-loss headwinds, while MedTech grew only 2.5% and missed management’s own expectations, particularly outside the U.S. Johnson & Johnson raised its 2026 sales and adjusted EPS outlook, but the earnings outlook still reflects meaningful dilution from its Firefly Bio acquisition and in vivo CAR-T collaboration.

Earnings Snapshot

The Bigger Story

Johnson & Johnson’s investment case remains centered on whether its newer Innovative Medicine products can more than offset erosion from older franchises, particularly STELARA, while MedTech returns to a more consistent growth profile.

That transition remained on track in Innovative Medicine. Oncology grew about 17%, and products including TREMFYA, DARZALEX, CARVYKTI, TECVAYLI, RYBREVANT/LAZCLUZE, SPRAVATO and CAPLYTA drove growth. However, STELARA’s decline created an approximately 690-basis-point drag on Innovative Medicine growth, illustrating the scale of the loss-of-exclusivity hurdle still facing the portfolio.

MedTech was the weaker link. The segment’s 2.5% growth reflected pressure in international surgery, competitive intensity in electrophysiology in Asia-Pacific, and lower Abiomed patient volumes. Management characterized these issues as concentrated and temporary, but the segment needs a clearer return to growth to support the company’s longer-term aspiration for double-digit growth by the end of the decade.

Revenue and Operating Performance

Innovative Medicine generated $16.8B in quarterly sales, rising 7.9% operationally. U.S. growth was 11.1%, compared with 3.0% outside the U.S., highlighting the importance of domestic uptake for newer launches and established brands.

In oncology, DARZALEX grew 15.6%, supported by share gains across lines of therapy and continued market expansion. CARVYKTI sales increased 35.2% as use expanded into earlier lines of multiple myeloma treatment, while TECVAYLI grew 77.3% following its earlier-line U.S. approval. RYBREVANT plus lazertinib grew 63.5%, supported by uptake in first- and second-line lung cancer.

Management also highlighted early uptake for INLEXZO, which generated approximately $200M in year-to-date sales and more than $90M in the third quarter. New patient starts increased 45% sequentially. The currently addressed high-risk non-muscle invasive bladder cancer population is relatively limited at roughly 4,000 patients, so broader label expansion will be important to the platform’s long-term opportunity.

Immunology showed the clearest evidence of portfolio replacement. TREMFYA grew 68.2%, supported by inflammatory bowel disease uptake and four points of share gains in both ulcerative colitis and Crohn’s disease. By contrast, STELARA sales declined 5.4% as biosimilar competition and newer therapeutic classes gained traction.

In neuroscience, CAPLYTA grew 66.1%, driven by uptake in adjunctive major depressive disorder and demand across bipolar disorder and schizophrenia. SPRAVATO grew 36% on continued physician adoption and patient demand in treatment-resistant depression.

MedTech sales rose 2.5% to $8.6B. U.S. growth of 4.8% was substantially better than the 0.1% growth reported internationally.

Cardiovascular sales grew 4.1%. Shockwave rose 17.2% as its coronary and peripheral products gained adoption, helped by new launches and U.S. reimbursement in office-based labs. Electrophysiology grew 4.4%, but competitive pressure in pulsed-field ablation was more pronounced in Asia-Pacific. Abiomed sales declined 1.5%, reflecting lower patient volumes.

Surgery sales declined 1%, partly due to divestitures, China’s volume-based procurement expansion, transformation-program effects, and disruption to ordering and tender activity in the Middle East. Vision grew 5.1%, including 7.1% growth in surgical vision, while Orthopaedics grew 3.4%, led by trauma and hip product launches.

Profitability and Margins

The sharp decline in GAAP earnings was primarily a special-items story rather than a reflection of the company’s underlying revenue performance.

GAAP net earnings fell to $210M, or $0.09 per share, after the company recorded approximately $7B of expenses related to the proposed talc litigation resolution, the Firefly Bio acquisition, and its in vivo CAR-T collaboration. Johnson & Johnson said its proposed ovarian talc litigation resolution carries a $5.5B cost and remains conditional on at least 95% claimant participation.

Adjusted results were also weaker. Adjusted EPS fell 7.5% to $2.59, while adjusted net earnings declined 6.8% to $6.3B. The Firefly transaction and CAR-T collaboration affected adjusted earnings as well, meaning the decline was not solely a GAAP litigation-charge issue.

Gross profitability was also under pressure. Cost of goods sold deleveraged by 150 basis points, driven by unfavorable product mix and increased intangible-amortization expense in Innovative Medicine, partly offset by MedTech tariff recoveries.

Innovative Medicine adjusted income-before-tax margin fell to 35.4% from 44.3%, largely due to approximately $1B of acquired in-process research and development expense related to Firefly Bio, transaction costs for the CAR-T collaboration, and product mix. MedTech adjusted income-before-tax margin improved to 22.9% from 21.0%, aided by tariff recoveries despite higher commercial investment.

Demand, Customers and Pricing

The underlying demand picture was strongest in Innovative Medicine. Management cited continued share gains for DARZALEX, CARVYKTI, TREMFYA, RYBREVANT, SPRAVATO and CAPLYTA, while ICOTYDE’s psoriasis launch has expanded the systemic-treatment market.

More than 20,000 patients have initiated ICOTYDE therapy through nearly 9,000 prescribers since launch, according to management. About 60% of treated patients were systemic-treatment naïve, suggesting the product is attracting new patients into advanced therapy rather than simply switching existing users. Management also said ICOTYDE now has broad access across national commercial plans.

MedTech demand appears steadier than reported segment growth suggests, but conversion has been inconsistent internationally. Management said underlying procedure trends remain stable across key markets. The immediate challenge is translating that demand into orders amid Chinese procurement changes, Middle East purchasing delays, and competitive pressure in electrophysiology.

What is Johnson & Johnson’s guidance for full-year 2026?

Johnson & Johnson raised its full-year outlook following the third quarter.

Management now expects:

The reported-sales midpoint increased by $100M from the prior outlook, while adjusted EPS guidance rose by $0.06 at the midpoint.

Management expects adjusted operating margin to decline by approximately 60 basis points for the year, an improvement from the prior expectation for a 75-basis-point decline. The Firefly Bio acquisition and CAR-T collaboration reduced margin by 150 basis points, according to the company; absent those transactions, management said base margins would improve.

For 2027, management said Firefly Bio and the CAR-T collaboration are expected to dilute adjusted EPS by a combined $1.36 per share. That creates a substantial earnings hurdle even if underlying operating growth remains healthy.

Balance Sheet, Cash Flow and Capital

Johnson & Johnson ended the quarter with approximately $17B of cash and marketable securities and $45B of debt, resulting in net debt of about $28B. It generated more than $6B of free cash flow during the quarter and reaffirmed full-year free-cash-flow guidance of $21B.

The company completed its $1B acquisition of Firefly Bio during the quarter and added a collaboration focused on in vivo CAR-T therapies for immune-mediated diseases. These investments expand its oncology and immunology pipeline, but they also carry near-term earnings and margin dilution.

Johnson & Johnson is also preparing to separate its DePuy Synthes Orthopaedics business by mid-2027. Management said it is leaning toward a spin-off as the preferred structure, though a final decision has not been announced.

What Investors Should Watch

1. STELARA erosion versus growth from replacement products

STELARA’s decline remains a major drag on Innovative Medicine growth. Investors should watch whether TREMFYA, ICOTYDE, INLEXZO, RYBREVANT and CARVYKTI can sustain enough growth to offset further biosimilar and competitive pressure.

2. MedTech’s return to more consistent growth

MedTech grew only 2.5%, with international revenue nearly flat. Improvement in electrophysiology, Abiomed and international surgery would support management’s view that the quarter reflected temporary execution and regional issues rather than weaker underlying demand.

3. Abiomed recovery

Abiomed declined 1.5% because of lower patient volumes. Management expects education and additional clinical evidence to help address physician-selection concerns, but a return to growth is needed to validate that the issue is temporary.

4. New-launch conversion

ICOTYDE, INLEXZO and RYBREVANT are increasingly important to the company’s growth algorithm. Patient uptake, payer access, label expansions and evidence readouts will determine whether these products can become material multibillion-dollar franchises.

5. Earnings dilution and capital allocation

The Firefly and CAR-T transactions are strategically aligned with high-growth therapeutic areas, but their $0.64 impact on 2026 adjusted EPS and expected $1.36 impact in 2027 raise the bar for underlying operating leverage. Investors should monitor whether revenue growth and margin improvement can absorb that dilution.

AlgovestIQ Takeaway

Johnson & Johnson delivered a stronger operating quarter than the GAAP earnings line suggests. Sales grew 6.0% operationally, Innovative Medicine expanded 7.9%, and the company raised its full-year sales and adjusted EPS outlook. Its portfolio transition is gaining traction, with newer medicines growing rapidly as the company manages through the decline of STELARA and other mature products.

The unresolved issue is MedTech. U.S. performance remained comparatively healthy, but weak international growth, lower Abiomed volumes, surgery pressure and electrophysiology competition constrained the segment. Management expects improvement in the fourth quarter, but that expectation now needs to translate into reported growth.

The central investment question is whether Johnson & Johnson can convert its new-product momentum into durable growth while restoring MedTech execution and absorbing the cost of pipeline investments. Evidence of sustained TREMFYA, ICOTYDE, INLEXZO and oncology growth, combined with a MedTech recovery, would strengthen the long-term thesis.

Conversely, faster-than-expected STELARA erosion, continued international MedTech weakness, or slower commercialization of new launches would make the path to double-digit growth by the end of the decade more dependent on future pipeline success and margin recovery.